You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. SBIR Phase I: Novel, Robust Process for Thin, Dense Ceramic Coatings

    SBC: SOLUTION SPRAY TECHNOLOGIES LLC            Topic: MI

    This Small Business Innovation Research Phase I project is aimed at development of a novel, low-cost process for manufacturing environmental barrier coatings (EBCs) for ceramic matrix composites (CMCs) in aviation gas turbines. A key limitation for CMC adoption is the unavailability of inexpensive, truly gas impervious EBCs to provide required CMC engine service life. While novel EBC compositions ...

    SBIR Phase I 2017 National Science Foundation
  2. Assembled Porous Silica Membranes for Biomolecule SPE

    SBC: ADVANCED MATERIALS TECHNOLOGY, INC.            Topic: 400

    Abstract Life sciences research and other critical bioanalytical applications would strongly benefit from faster and higher efficiency sample preparation processes Sample preparation before high resolution analytical methods such as HPLC or LC MS can require effort and cost nearly equivalent to the actual sample analysis and data reduction Often sample preparation for proteomic glycoproteom ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Targeting the checkpoint regulator VISTA for treatment of inflammatory disease

    SBC: Immunext, Inc.            Topic: R

    ImmuNext has identified and developed a putative lead anti VISTA monoclonal antibody mAb that we aim to bring to the clinic for the treatment of human autoimmune disease VISTA is a member of the highly successful negative checkpoint regulator NCR family of drug targets whose members have demonstrated proven efficacy in inducing long term remissions in human cancers We contend that antibodie ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Bioimpedance based Intracranial Mapping for Monitoring Evolving TBI

    SBC: RYTEK MEDICAL INC            Topic: 105

    ABSTRACT Approximately million individuals suffer from traumatic brain injury TBI annually with over expected to die as a result of their injury In these most severe cases patients are typically admitted to the intensive care unit ICU for continuous monitoring and treatment of their injury Standard monitoring includes implantation of an intracranial pressure ICP sensor arterial ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Design and Development of Immunotolerant S. aureus Biotherapies

    SBC: Lyticon LLC            Topic: R

    The increasing incidence of multi drug resistance in Staphylococcus aureus and other bacteria represents a public health crisisTwo thirds of hospital associated Saureus infections andof those acquired in the community are now methicillin resistantMRSAMRSA causes rtinfections in the US each yearand it is responsible for half of all US deaths caused by drug resistant bacteriaThis threat to public he ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF

    SBC: CELDARA MEDICAL, LLC            Topic: NHLBI

    DESCRIPTIONprovided by applicantIdiopathic pulmonary fibrosisIPFkills aboutpersons in the United States each yearThere are currently aroundAmericans afflicted with this fatal disease that typically results in death withinyearsThis year alone another approximatelyAmericans will receive this devastating diagnosisWhile two recently approved drugs reduce the time to decline in certain lung parametersa ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Developing an integrated sorting and single cell analysis tool for the analysis of rare T Cells subsets in Autoimmunity

    SBC: ISOPLEXIS CORPORATION            Topic: R

    Autoimmune disease AD affects up to million Americans which costs approximately $ billion on health care annually and accounts for one of the leading causes of death in women T cells and cytokine function play an important role in autoimmune diseases such as Type Diabetes Multiple Sclerosis Rheumatoid Arthritis RA and Systemic Lupus Erythematosus SLE The most successful auto i ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Development of GIFT4: a B cell focused immunotherapy for cancer

    SBC: CELDARA MEDICAL, LLC            Topic: NCI

    Project Summary Our goal is to develop a novel immunotherapy for the treatment of melanomaand potentially a wide array of tumorsAlthough surveillance by the immune system eliminates cancer cells in some instancestumor cells have developed a variety of mechanisms to escape immune recognition often resulting in tumor outgrowthImmune checkpoint inhibitorse gipilimumabnivolumaband pembrolizumaband cel ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Precision quality check of immunotherapeutics via single-cell cytokine mapping

    SBC: ISOPLEXIS CORPORATION            Topic: 102

    Adoptive transfer of autologous T cells engineered to express chimeric antigen receptorsCARshas emerged as a promising immunotherapy for patients with hematologic malignanciessuch as CDCARs in leukemias and lymphomasHoweverchallenges remain in terms of manufacturing consistency and the functional profile of the CAR T cell productsince infused cellsasliving drugscan be activated and release a varie ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Enhanced Oxidative Dehydrogenation of Ethane with Facilitated Transport Membranes for Low Cost Production of Ethylene

    SBC: COMPACT MEMBRANE SYSTEMS, INC.            Topic: 17a

    Ethylene demand is expected to increase by 50% domestically and worldwide over the next 5 years. Much of this and future growth is likely to be met from shale gas based ethane. Dr. Anne Gaffney of the US-DOE has invented a mixed metal oxide catalyst, M1, for the oxidative dehydrogenation of ethane (C2- ODH) to ethylene at high conversions and very high selectivities. A major hurdle for commercial ...

    SBIR Phase I 2017 Department of Energy
US Flag An Official Website of the United States Government